Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Urology

• Publication date

  1999-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0022-5347(05)68241-9PMID 10524938
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuroendocrine peptides in the prostate

  2004cited by this paper
• Granin‐A, parathyroid hormone‐related protein, and calcitonin gene products in neuroendocrine prostate cancer

  1998cited by this paper
• Neuroendocrine differentiation in prostatic carcinoma: An update

  1998cited by this paper
• Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells.

  1998cited by this paper
• Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors

  1998cited by this paper
• Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings?

  1997cited by this paper
• The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy.

  1997cited by this paper
• Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium.

  1997cited by this paper
• Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment.

  1997cited by this paper
• Neuroendocrine differentiation and hormone‐refractory prostate cancer

  1996cited by this paper
• Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy.

  1996cited by this paper
• Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model

  1996cited by this paper
• Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.

  1995cited by this paper
• [Cancer of the prostate. 2. Physiology and cellular development].

  1995cited by this paper
• Enhanced expression of p53 mRNA and protein in the regressing rat ventral prostate gland.

  1994cited by this paper
• Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP.

  1994cited by this paper
• The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research.

  1994cited by this paper
• Hormonal regulation of transforming growth factor beta-2 expression in human prostate cancer.

  1993cited by this paper
• Hormonal regulation of transforming growth factor β-2 expression in human prostate cancer

  1993cited by this paper
• Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

  1993cited by this paper
• Neuroendocrine differentiation in human prostatic carcinoma.

  1992cited by this paper
• Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications.

  1992cited by this paper
• Neuroendocrine differentiation in human prostatic carcinoma

  1992cited by this paper
• Cyclic AMP induces transforming growth factor beta 2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3.

  1992cited by this paper
• Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications

  1992cited by this paper
• Investigation on serum neurone‐specific enolase in prostate cancer diagnosis and monitoring: Comparative study of a multiple tumor marker assay

  1991cited by this paper
• Elevated plasma chromogranin-A concentrations in prostatic carcinoma.

  1991cited by this paper
• Relation of endocrine‐paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate

  1991cited by this paper
• Neuroendocrine differentiation in prostatic carcinoma.

  1987cited by this paper
• Detection of specific sequences among DNA fragments separated by gel electrophoresis.

  1975cited by this paper

• Prostate-Specific Membrane Antigen PET/Computed Tomography: Pearls and Pitfalls.

  2025cites this paper
• Human serum albumin or polyvinyl alcohol can only partially replace human plasma during in vitro red cell production from PBMC

  2025cites this paper
• PROCA11 early activation fuels prostate cancer neuroendocrine traits by regulating cell survival and migration

  2025cites this paper
• Oncofetal protein glypican‐3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer

  2023influential citation
• Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor

  2023cites this paper
• Prostate-Specific Membrane Antigen PET/Computed Tomography: Pearls and Pitfalls.

  2023cites this paper
• The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer

  2022cites this paper
• An Update on the Management of Mixed Neuroendocrine-Non-neuroendocrine Neoplasms (MiNEN)

  2022cites this paper
• Neuroendocrine cells of the prostate: Histology, biological functions, and molecular mechanisms

  2021cites this paper
• Molecular and Functional Links between Neurodevelopmental Processes and Treatment-Induced Neuroendocrine Plasticity in Prostate Cancer Progression

  2021cites this paper
• Molecular events in neuroendocrine prostate cancer development

  2021cites this paper
• 177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements

  2021cites this paper
• The inhibitory effect of melatonin on human prostate cancer

  2021cites this paper
• Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer

  2020cites this paper
• Cellular rewiring in lethal prostate cancer: the architect of drug resistance

  2020cites this paper
• SLX4IP Promotes Telomere Maintenance in Androgen Receptor–Independent Castration-Resistant Prostate Cancer through ALT-like Telomeric PML Localization

  2020cites this paper
• Senescence and castration resistance in prostate cancer: A review of experimental evidence and clinical implications.

  2020cites this paper
• Morphologic Spectrum of Neuroendocrine Tumors of the Prostate: An Updated Review.

  2020cites this paper
• Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now?

  2019cites this paper
• Evolving concepts in prostatic neuroendocrine manifestations: from focal divergent differentiation to amphicrine carcinoma.

  2019cites this paper
• The Genomics of Prostate Cancer: A Historic Perspective.

  2019cites this paper
• Insulin Enhances Migration and Invasion in Prostate Cancer Cells by Up-Regulation of FOXC2

  2019cites this paper
• Lineage relationship between prostate adenocarcinoma and small cell carcinoma

  2019cites this paper
• PEG10 is associated with treatment-induced neuroendocrine prostate cancer.

  2019cites this paper
• Radionuclide Therapy of Metastatic Prostate Cancer.

  2019cites this paper
• Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms

  2019cites this paper
• HOTAIR is a REST-regulated lncRNA that promotes neuroendocrine differentiation in castration resistant prostate cancer.

  2018cites this paper
• ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis.

  2018cites this paper
• Mechanisms of treatment induced cell plasticity in prostate cancer

  2018influential citation
• EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.

  2018cites this paper
• Evolution of Melanoma Antigen-A11 (MAGEA11) During Primate Phylogeny

  2018cites this paper
• Role of Stromal Paracrine Signals in Proliferative Diseases of the Aging Human Prostate

  2018cites this paper
• Effect of A549 neuroendocrine differentiation on cytotoxic immune response

  2018cites this paper
• AR AND CgA in situ DETECTION AS PROGNOSTIC CLINICAL MARKERS IN PROSTATE ADENOCARCINOMA

  2018cites this paper
• The Genomics of Prostate Cancer: emerging understanding with technologic advances

  2018cites this paper
• Biology and evolution of poorly differentiated neuroendocrine tumors

  2017cites this paper
• Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer

  2017cites this paper
• MAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells

  2017cites this paper
• A Prominent Couple : the TMPRSS2:ERG Gene Fusion in Aggressive Prostate Cancer

  2017influential citation
• Midkine in Advanced Prostate Cancer - Biological Impact and Biomarker Potential

  2017cites this paper
• The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

  2017cites this paper
• The Missing Link in the Diagnostic Pathway of Prostate Cancer

  2017cites this paper
• High glucose induces N-linked glycosylation-mediated functional upregulation and overexpression of Cav3.2 T-type calcium channels in neuroendocrine-like differentiated human prostate cancer cells.

  2017cites this paper
• Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications

  2017cites this paper
• REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling

  2016cites this paper
• Neuronal Trans‐Differentiation in Prostate Cancer Cells

  2016cites this paper
• Chapter 18 – Neuroendocrine Prostate Cancer

  2016cites this paper
• Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer

  2016cites this paper
• The aryl hydrocarbon receptor nuclear translocator (ARNT) transcriptional co-regulator complex: Effects on estrogen and hypoxia signaling

  2016cites this paper
• Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway.

  2016cites this paper
• The many ways to make a luminal cell and a prostate cancer cell.

  2015cites this paper
• β-Adrenergic Receptor Signaling in Prostate Cancer

  2015influential citation
• Posttranscriptional regulation of T-type Ca(2+) channel expression by interleukin-6 in prostate cancer cells.

  2015cites this paper
• Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor*

  2015cites this paper
• Malignant cell‐derived extracellular vesicles express different chromogranin epitopes compared to prostasomes

  2015cites this paper
• Functional upregulation of the H2S/Cav3.2 channel pathway accelerates secretory function in neuroendocrine-differentiated human prostate cancer cells.

  2015cites this paper
• Neuroendocrine differentiation: The mysterious fellow of colorectal cancer.

  2015cites this paper
• Leading causes of castration-resistant

  2015cites this paper
• Primate-Specific Multi-Functional Androgen Receptor Coregulator and Proto-Oncogene Melanoma Antigen-A11 (MAGE-A11)

  2015cites this paper
• Cancer (stem) cell differentiation: An inherent or acquired property?

  2015cites this paper
• Leading causes of castration-resistant prostate cancer

  2015cites this paper
• Small cell carcinoma of the prostate

  2014cites this paper
• Autophagy Pathway Is Required for IL-6 Induced Neuroendocrine Differentiation and Chemoresistance of Prostate Cancer LNCaP Cells

  2014cites this paper
• Epigenetic, Genetic, and Acquired Regulation of Cav3 T-Type Calcium Channel Expression and Function in Tumor Growth and Progression

  2014cites this paper
• Somatostatin Analogs and Disease Control in Castration-resistant Prostate Cancer: Different Biological Behavior? Case Series and Review of the Literature

  2014cites this paper
• Functional characterisation of phosphodiesterase 4D7 in prostate cancer

  2014cites this paper
• TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation

  2014cites this paper
• The Steroid Receptor Coactivator-3 Is Required for Developing Neuroendocrine Tumor in the Mouse Prostate

  2014cites this paper
• Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b~25.

  2014cites this paper
• Androgen-Targeted Therapy-Induced Epithelial Mesenchymal Plasticity and Neuroendocrine Transdifferentiation in Prostate Cancer: An Opportunity for Intervention

  2014cites this paper
• The molecular basis for ethnic variation and histological subtype differences in prostate cancer

  2013cites this paper
• p21-Activated kinase 4 promotes prostate cancer progression through CREB

  2013cites this paper
• Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.

  2013cites this paper
• Melatonin: a pleiotropic molecule of natural origin. Evaluation of the different therapeutic activities in animal models and / or human patients and a study of the metabolic-biochemical pathways related to them.

  2013cites this paper
• Neuroendocrine differentiation of prostate cancer.

  2013cites this paper
• Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells.

  2013influential citation
• Human ASH‐1 Promotes Neuroendocrine Differentiation in Androgen Deprivation Conditions and Interferes With Androgen Responsiveness in Prostate Cancer Cells

  2013cites this paper
• Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.

  2012cites this paper
• Melanoma Antigen-A11 (MAGE-A11) Enhances Transcriptional Activity by Linking Androgen Receptor Dimers*

  2012cites this paper
• Complete Chemotherapeutic Regression of a Non-Metastatic Case of Primary Pure Small Cell Carcinoma of the Prostate

  2012cites this paper
• MARCATORI IMMUNOISTOCHIMICI E MOLECOLARI AD IMPATTO PROGNOSTICO E PREDITTIVO DI RISPOSTA ALLA TERAPIA IN AMBITO NEOPLASTICO IMMUNOHISTOCHEMICAL AND MOLECULAR PROGNOSTIC/PREDICTIVE MARKERS IN NEOPLASTIC DISEASES

  2012cites this paper
• Mixed Primary Small Cell Carcinoma Of Prostate And Primary Adenocarcinoma Of Prostate: A Report Of Two Cases And Review Of The Literature On Small Cell Carcinoma Of Prostate

  2012cites this paper
• Stem‐Like Cells with Luminal Progenitor Phenotype Survive Castration in Human Prostate Cancer

  2012cites this paper
• Cytoskeleton Reorganization as an Alternative Mechanism of Store-Operated Calcium Entry Control in Neuroendocrine-Differentiated Cells

  2012cites this paper
• PC 3 Is a Cell Line Characteristic of Prostatic Small Cell Carcinoma

  2012cites this paper
• LNCaP prostate cancer cells with autocrine interleukin‐6 expression are resistant to IL‐6‐induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling

  2012cites this paper
• Carbidopa abrogates L‐dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression

  2012cites this paper
• Alma Mater Studiorum - Università di Bologna DOTTORATO DI RICERCA IN ONCOLOGIA E PATOLOGIA SPERIMENTALE PROGETTO N. 1 ONCOLOGIA

  2012cites this paper
• Androgen-sensitive microsomal signaling networks coupled to the proliferation and differentiation of human prostate cancer cells.

  2011cites this paper
• MnSOD drives neuroendocrine differentiation, androgen independence, and cell survival in prostate cancer cells.

  2011cites this paper
• Clinical Analysis of Patients with Small Cell Prostate Carcinoma

  2011cites this paper
• Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma.

  2011cites this paper
• IGFBP2 as an Immunohistochemical Marker for Prostatic Adenocarcinoma

  2011cites this paper
• PC3 is a cell line characteristic of prostatic small cell carcinoma

  2011cites this paper
• Molecular Targeting of Prostate Cancer During Androgen Ablation: Inhibition of CHES1/FOXN3

  2010cites this paper
• Clinical significance of polymorphism and expression of chromogranin a and endothelin-1 in prostate cancer.

  2010cites this paper
• UNIVERSITÁ DEGLI STUDI DI MILANO FACOLTÁ DI MEDICINA E CHIRURGIA

  2010cites this paper
• Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails

  2010cites this paper
• Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells

  2010cites this paper
• The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities

  2010cites this paper